Literature DB >> 22886010

Can the treatment of vascular risk factors slow cognitive decline in Alzheimer's disease patients?

Florence Richard1, Florence Pasquier.   

Abstract

Dementia is a widespread disorder with major medical, economic and societal costs. Controlling vascular conditions could be one way of delaying the progression of Alzheimer's disease (AD). In fact, vascular risk factors are implicated in AD occurrence. However, it has not been clearly determined whether these vascular factors also affect disease progression itself and thus whether controlling vascular conditions can slow this progression. The treatment of vascular risk factors could have an impact on disease progression by slowing the development of the vascular component. In the present article, we review the potential value of managing hypertension, diabetes, hypercholesterolemia or global vascular risk factors in AD patients.

Entities:  

Mesh:

Year:  2012        PMID: 22886010     DOI: 10.3233/JAD-2012-121012

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  7 in total

1.  Decreased white matter integrity in neuropsychologically defined mild cognitive impairment is independent of cortical thinning.

Authors:  Nikki H Stricker; David H Salat; Jessica M Foley; Tyler A Zink; Ida L Kellison; Craig P McFarland; Laura J Grande; Regina E McGlinchey; William P Milberg; Elizabeth C Leritz
Journal:  J Int Neuropsychol Soc       Date:  2013-07-01       Impact factor: 2.892

2.  Reduction of Cognitive Decline in Patients with or at High Risk for Diabetes.

Authors:  Gladys E Maestre
Journal:  Curr Geriatr Rep       Date:  2017-07-18

Review 3.  Roles of vascular and metabolic components in cognitive dysfunction of Alzheimer disease: short- and long-term modification by non-genetic risk factors.

Authors:  Naoyuki Sato; Ryuichi Morishita
Journal:  Front Aging Neurosci       Date:  2013-11-05       Impact factor: 5.750

Review 4.  Brain alterations and clinical symptoms of dementia in diabetes: aβ/tau-dependent and independent mechanisms.

Authors:  Naoyuki Sato; Ryuichi Morishita
Journal:  Front Endocrinol (Lausanne)       Date:  2014-09-05       Impact factor: 5.555

5.  Treatable Vascular Risk and Cognitive Performance in Persons Aged 35 Years or Older: Longitudinal Study of Six Years.

Authors:  M E A van Eersel; H Joosten; R T Gansevoort; J P J Slaets; G J Izaks
Journal:  J Prev Alzheimers Dis       Date:  2019

Review 6.  Potential Roles of Glucagon-Like Peptide-1 and Its Analogues in Dementia Targeting Impaired Insulin Secretion and Neurodegeneration.

Authors:  Sidharth Mehan; Sonalika Bhalla; Ehraz Mehmood Siddiqui; Nidhi Sharma; Ambika Shandilya; Andleeb Khan
Journal:  Degener Neurol Neuromuscul Dis       Date:  2022-03-07

7.  Pharmacological treatment of increased vascular risk and cognitive performance in middle-aged and old persons: six-year observational longitudinal study.

Authors:  Marlise E A van Eersel; Sipke T Visser; Hanneke Joosten; Ron T Gansevoort; Joris P J Slaets; Gerbrand J Izaks
Journal:  BMC Neurol       Date:  2020-06-12       Impact factor: 2.474

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.